Type 1 Diabetes Mellitus
Conditions
Brief summary
(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an over-the-counter dietary supplement. The dose the investigators are giving in this study is higher than the usual recommended dosage taken as a supplement for certain medical conditions. (3) To study combined effects of fluoxetine and DHEA during low blood glucose. In the present study, the investigators will measure the participant's body's responses to hypoglycemia when given fluoxetine or DHEA or fluoxetine and DHEA or a placebo (a pill with no fluoxetine or DHEA). Approximately 64 individuals with type 1 diabetes will take part in this study.
Interventions
DRUGPlacebo Oral Tablet
There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
DRUGFluoxetine
There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
DRUGDHEA
There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
DRUGFluoxetine and DHEA
There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
Sponsors
University of Maryland, Baltimore
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Participants will be randomized into 2 groups. Group 1 will consist of a random order of Protocol 1 and Protocol 5. Group 2 will consist of a randomized order of Protocols 2, 3, 4
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* 64 (32 males, 32 females) T1DM patients aged 18-50 yr. * HbA1c \< 11.0% * No clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc) * Body mass index \< 40kg · m-2
Exclusion criteria
* Pregnancy * Subjects unable to give voluntary informed consent * Subjects on anticoagulant drugs, anemic or with known bleeding diatheses * Subjects taking any of the following medications will be excluded: Non-selective Beta Blockers, Sedative-Hypnotics, Anticonvulsants, Antiparkinsonian drugs, Antipsychotics, Antidepressants, Mood stabilizers, CNS Stimulants, Opioids, Hallucinogens * Subjects with a recent medical illness or past history of severe depression, mania or psychotic disease * Subjects that score greater than 50 on the depression scale * Subjects unwillingness or inability to comply with approved contraception measures * Abnormal results following screening tests and physical examination that are clinically significant * Subjects with a history of severe uncontrolled hypertension (i.e., blood pressure greater than 160/100), heart disease, cerebrovascular incidents * Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmias, ischemic tachycardia, S-T segment deviations, etc.) from history or from cardiac stress testing in subjects ≥ 40 years old. * Pneumonia * Hepatic Failure/Jaundice * Creatinine greater than 1.6 mg/dl * Acute Cerebrovascular/ Neurological deficit * Fever greater than 38 °C Screening Laboratory Tests
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the level of catecholamines in plasma | An average of 3 years |
Countries
United States
Contacts
Primary ContactMaka Siamashvili, MD
Backup ContactVanessa Briscoe, PhD
Outcome results
None listed